{"success":true,"data":{"pressRelease":{"id":"132319","rtpr_id":"nGNX3j8PQR","ticker":"ARDX","exchange":"NASDAQ","all_tickers":["ARDX"],"title":"Ardelyx to Participate in Upcoming Investor Conferences","author":"Globe Newswire","published_at":"2026-09-01T11:30:00.105Z","article_body":"WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq:\nARDX), (“Ardelyx” or the “Company”) a commercial-stage\nbiopharmaceutical company focused on the development and commercialization of\ninnovative medicines that meet significant unmet medical needs, today\nannounced its participation in the following investor conferences:\n\nCiti's 2026 Biopharma Back to School Conference\nLocation: New York, NY\nInvestor Meetings: Wednesday, September 9\n\n2026 Cantor Global Healthcare Conference\nLocation: New York, NY\nFireside Chat: Thursday, September 10 at 11:30 AM ET\nInvestor Meetings: Thursday, September 10\n\nMorgan Stanley 24th Annual Global Healthcare Conference\nLocation: New York, NY\nFireside Chat: Wednesday, September 16 at 7:45 AM ET\nInvestor Meetings: Wednesday, September 16\n\nTo access a live webcast of the fireside chats, please visit the Events and\nPresentations page within the Ardelyx website at ir.ardelyx.com\n(https://www.globenewswire.com/Tracker?data=NiAUhgADvgBX9L8OMViEcpAy2UDOyIpBH1qgeZmQJ6NaDkX8fsnenCYCLDTTN5jYvKhg3Czh8hQQdjRnelIvb-IO-KahW2vKCg18eQcXl9JS9Xrba7mY0fOPSbt6yKEz).\nReplays will be available following the event.\n\nAbout Ardelyx, Inc.\nArdelyx is a commercial-stage biopharmaceutical company focused on the\ndevelopment and commercialization of innovative medicines that meet\nsignificant unmet medical needs. Ardelyx has two commercial products approved\nin the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The\ncompany’s pipeline includes the Phase 3 development of IBSRELA for chronic\nidiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor\nwith potential application across multiple therapeutic areas. Ardelyx works\nwith partners to develop and commercialize our products outside of the United\nStates. For more information, please visit https://ardelyx.com/ and connect\nwith us on X (formerly known as Twitter)\n(https://www.globenewswire.com/Tracker?data=OR446KvI8D5nkCvFv76TSoCTycPjfdZpIvYW5BtvOg2zfv1LegWu2GYxpqxJIGDGRWORBM0MzoA_oahAl8KEEVGA-PkGB7t3GYgPHmMvzF4cm45mqm_V0ObUVNaID6vU),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=7syM_uBg2GdUIkOBrJFKmlDCA33e2zFT-Y16VkbVIfx1WznKTgKAAUl5XbpT4az-NDD95jMkLUZzmHlDTPpXSFQd2OjckrEJ9KK5ZsoirH8=)\nand Facebook\n(https://www.globenewswire.com/Tracker?data=ePzmsTqFFeneYZLsdbTr5Wm5bJ1gwBTFWBaDSAqXahDqr9QkuWBzOunRVBd8N9XsEmltUCdKlcQ2TteVmR9vsOTDIONomNivyzfSbWBNIXU=).\n\nInvestor & Media Contact: \nLisa Caperelli\nlcaperelli@ardelyx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cee4ae6d-7a85-44bf-9c02-87e7fa934ec2)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX3j8PQR","title":"Ardelyx to Participate in Upcoming Investor Conferences","author":"Globe Newswire","ticker":"ARDX","created":"2026-09-01T11:30:00.105Z","tickers":["ARDX"],"exchange":"NASDAQ","article_body":"WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq:\nARDX), (“Ardelyx” or the “Company”) a commercial-stage\nbiopharmaceutical company focused on the development and commercialization of\ninnovative medicines that meet significant unmet medical needs, today\nannounced its participation in the following investor conferences:\n\nCiti's 2026 Biopharma Back to School Conference\nLocation: New York, NY\nInvestor Meetings: Wednesday, September 9\n\n2026 Cantor Global Healthcare Conference\nLocation: New York, NY\nFireside Chat: Thursday, September 10 at 11:30 AM ET\nInvestor Meetings: Thursday, September 10\n\nMorgan Stanley 24th Annual Global Healthcare Conference\nLocation: New York, NY\nFireside Chat: Wednesday, September 16 at 7:45 AM ET\nInvestor Meetings: Wednesday, September 16\n\nTo access a live webcast of the fireside chats, please visit the Events and\nPresentations page within the Ardelyx website at ir.ardelyx.com\n(https://www.globenewswire.com/Tracker?data=NiAUhgADvgBX9L8OMViEcpAy2UDOyIpBH1qgeZmQJ6NaDkX8fsnenCYCLDTTN5jYvKhg3Czh8hQQdjRnelIvb-IO-KahW2vKCg18eQcXl9JS9Xrba7mY0fOPSbt6yKEz).\nReplays will be available following the event.\n\nAbout Ardelyx, Inc.\nArdelyx is a commercial-stage biopharmaceutical company focused on the\ndevelopment and commercialization of innovative medicines that meet\nsignificant unmet medical needs. Ardelyx has two commercial products approved\nin the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The\ncompany’s pipeline includes the Phase 3 development of IBSRELA for chronic\nidiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor\nwith potential application across multiple therapeutic areas. Ardelyx works\nwith partners to develop and commercialize our products outside of the United\nStates. For more information, please visit https://ardelyx.com/ and connect\nwith us on X (formerly known as Twitter)\n(https://www.globenewswire.com/Tracker?data=OR446KvI8D5nkCvFv76TSoCTycPjfdZpIvYW5BtvOg2zfv1LegWu2GYxpqxJIGDGRWORBM0MzoA_oahAl8KEEVGA-PkGB7t3GYgPHmMvzF4cm45mqm_V0ObUVNaID6vU),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=7syM_uBg2GdUIkOBrJFKmlDCA33e2zFT-Y16VkbVIfx1WznKTgKAAUl5XbpT4az-NDD95jMkLUZzmHlDTPpXSFQd2OjckrEJ9KK5ZsoirH8=)\nand Facebook\n(https://www.globenewswire.com/Tracker?data=ePzmsTqFFeneYZLsdbTr5Wm5bJ1gwBTFWBaDSAqXahDqr9QkuWBzOunRVBd8N9XsEmltUCdKlcQ2TteVmR9vsOTDIONomNivyzfSbWBNIXU=).\n\nInvestor & Media Contact: \nLisa Caperelli\nlcaperelli@ardelyx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cee4ae6d-7a85-44bf-9c02-87e7fa934ec2)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-01T11:30:00.154172719Z","server_sent_at_ms":1788262200154},"received_at":"2026-09-01T11:30:00.320Z","source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354015/0/en/ardelyx-to-participate-in-upcoming-investor-conferences.html"},"analysis":{"id":"121218","press_release_id":"132319","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Ardelyx announced it will participate in three upcoming investor conferences, including sessions hosted by Citi, Cantor Fitzgerald, and Morgan Stanley.\n\nManagement is scheduled to hold fireside chats at the Cantor Global Healthcare Conference on September 10 and the Morgan Stanley Global Healthcare Conference on September 16.\n\nLive webcasts of the presentations will be available on the Ardelyx investor relations website, with replays to follow.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference attendance."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Lisa Caperelli","role":"Investor & Media Contact"}],"products":["IBSRELA","XPHOZAH","RDX10531"],"companies":[{"name":"Citi","relationship":"conference host"},{"name":"Cantor Fitzgerald","relationship":"conference host"},{"name":"Morgan Stanley","relationship":"conference host"},{"name":"Ardelyx Inc.","ticker":"ARDX"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor relations announcement regarding participation in upcoming conferences with no material financial or clinical disclosures."},"tickerRelevance":{"others":[],"primary":"ARDX"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small_mid_cap","eventGravity":"routine_ir_conference_attendance"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Ardelyx announced it will participate in three upcoming investor conferences, including sessions hosted by Citi, Cantor Fitzgerald, and Morgan Stanley.\n\nManagement is scheduled to hold fireside chats at the Cantor Global Healthcare Conference on September 10 and the Morgan Stanley Global Healthcare Conference on September 16.\n\nLive webcasts of the presentations will be available on the Ardelyx investor relations website, with replays to follow.","key_figures":null,"named_entities":{"people":[{"name":"Lisa Caperelli","role":"Investor & Media Contact"}],"products":["IBSRELA","XPHOZAH","RDX10531"],"companies":[{"name":"Citi","relationship":"conference host"},{"name":"Cantor Fitzgerald","relationship":"conference host"},{"name":"Morgan Stanley","relationship":"conference host"},{"name":"Ardelyx Inc.","ticker":"ARDX"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-01T11:51:25.730Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small_mid_cap","eventGravity":"routine_ir_conference_attendance"}},"durationMs":88177,"modelName":"glm-4.7"}}